Zoetis Inc.

ZTS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $2.67B $2.49B $2.34B $2.11B $2.04B $1.64B $1.50B $1.43B
Depreciation & Amortization $487.0M $497.0M $491.0M $465.0M $448.0M $441.0M $412.0M $308.0M
Depreciation $330.0M $327.0M $306.0M $272.0M $244.0M $211.0M $175.0M $152.0M
Amortization $157.0M $170.0M $185.0M $193.0M $204.0M $230.0M $237.0M $157.0M
Stock-Based Compensation $83.0M $74.0M $60.0M $62.0M $58.0M $59.0M $67.0M $53.0M
Net Cash from Operating Activities $2.90B $2.95B $2.35B $1.91B $2.21B $2.13B $1.80B $1.79B
Investing Activities
Capital Expenditures $621.0M $655.0M $732.0M $586.0M $477.0M $453.0M $460.0M $338.0M
Business Acquisitions $0 $0 $1.88B
Net Cash from Investing Activities $-748.0M $-315.0M $-777.0M $-883.0M $-458.0M $-572.0M $-504.0M $-2.26B
Financing Activities
Dividends Paid
Stock Repurchases $3.24B $1.86B $1.09B $1.59B $743.0M $250.0M $626.0M $698.0M
Net Cash from Financing Activities $-1.87B $-2.66B $-3.11B $-904.0M $-1.86B $123.0M $-951.0M $533.0M
Net Change in Cash $325.0M $-54.0M $-1.54B $96.0M $-119.0M $1.67B $332.0M $38.0M
Free Cash Flow $2.28B $2.30B $1.62B $1.33B $1.74B $1.67B $1.34B $1.45B
← Newer Page 1 of 2 Older →